Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Common Equity (2019 - 2025)

Keros Therapeutics' Common Equity history spans 7 years, with the latest figure at $303.1 million for Q4 2025.

  • For Q4 2025, Common Equity fell 46.96% year-over-year to $303.1 million; the TTM value through Dec 2025 reached $303.1 million, down 46.96%, while the annual FY2025 figure was $303.1 million, 46.96% down from the prior year.
  • Common Equity reached $303.1 million in Q4 2025 per KROS's latest filing, down from $703.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $728.9 million in Q1 2025 to a low of $211.2 million in Q2 2022.
  • Average Common Equity over 5 years is $381.5 million, with a median of $314.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: soared 1098.8% in 2021, then plummeted 46.96% in 2025.
  • A 5-year view of Common Equity shows it stood at $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then crashed by 46.96% to $303.1 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Common Equity are $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025).